 |
8 Diseases |  |
2 Trials |
|
2 Trials |  |
21 News |  |
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Journal: TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. (Pubmed Central) - May 27, 2021
P2
TriMixDC-MEL IPI treatment results in robust CD8+ T-cell responses in a meaningful portion of stage III or IV melanoma patients, and obviously in patients with a clinical response. The levels of polyfunctional and multiantigen T-cell responses measured in patients with a complete response, particularly in patients evidently cured after 5+ years of follow-up, may provide a benchmark for the level of immune stimulation needed to achieve a durable clinical remission.
- || TriMix-DC (TriMix technology-based in vivo mRNA immunotherapy) / eTheRNA immunotherapies
Clinical, P2 data, Journal, PD(L)-1 Biomarker, IO Biomarker: A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. (Pubmed Central) - Dec 16, 2020
TriMixDC-MEL id/iv as adjuvant therapy is tolerable and may improve the 1-year disease-free survival rate. Combination of optimized autologous monocyte-derived DC-formulations warrants further investigation in combination with currently approved adjuvant therapy options.
- TriMix-DC (TriMix technology-based in vivo mRNA immunotherapy) / eTheRNA immunotherapies
[VIRTUAL] Step by step optimization of mRNA-electroporated dendritic cells during a phase I / II vaccine trial in stage IV cutaneous melanoma patients: an increase in survival correlates with higher immunoscore in metastases, and upregulation of PEBP1 in peripheral blood (Stream 4) - Sep 20, 2020 - Abstract #ADO2020ADO_89;
P1/2
Our data suggests optimal maturation stimulus and delivery route of DCs, and confirm early‐on biomarkers we described earlier. This will help to maximize vaccine effects in upcoming trials against various cancers.
- | TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies, Yervoy (ipilimumab) / BMS
Trial completion, Combination therapy: TriMix-Ipi: Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - May 24, 2017
P2, N=39, Completed, Sponsor: Bart Neyns
This will help to maximize vaccine effects in upcoming trials against various cancers. Active, not recruiting --> Completed
- TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies
Trial completion, Enrollment change, Trial primary completion date: Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients (clinicaltrials.gov) - Nov 5, 2014
P1/2, N=28, Completed, Sponsor: Radboud University
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=35 --> 28 | Trial primary completion date: Apr 2012 --> Nov 2014
- TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies
Trial primary completion date: A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - May 4, 2014
P1, N=18, Completed, Sponsor: Bart Neyns
Active, not recruiting --> Completed | N=35 --> 28 | Trial primary completion date: Apr 2012 --> Nov 2014 Trial primary completion date: Sep 2013 --> Nov 2013
- TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies
Trial completion date: A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - May 4, 2014
P1, N=18, Completed, Sponsor: Bart Neyns
Trial primary completion date: Sep 2013 --> Nov 2013 Trial completion date: Sep 2014 --> May 2014
- TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies
Trial completion: A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - May 4, 2014
P1, N=18, Completed, Sponsor: Bart Neyns
Trial completion date: Sep 2014 --> May 2014 Active, not recruiting --> Completed
- TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies, Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy: TriMix-Ipi: Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Aug 15, 2012
P2, N=39, Active, not recruiting, Sponsor: Bart Neyns
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies
Enrollment closed: A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Mar 20, 2012
P1, N=18, Active, not recruiting, Sponsor: Bart Neyns
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting